September 26, 2019 06:57 AM EDTUpdated 10:14 AM
Deals

Is the FTC about to force Roche to di­vest a key he­mo­phil­ia pro­gram be­fore green-light­ing Spark buy­out?

John Carroll

Editor & Founder

Mizuho Se­cu­ri­ties an­a­lyst Difei Yang has been con­sult­ing with the FTC ex­perts at Allen & Overy over Roche’s long-de­layed $4.3 bil­lion Spark Ther­a­peu­tics buy­out. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times